000128973 001__ 128973
000128973 005__ 20240228143401.0
000128973 0247_ $$2doi$$a10.1007/s00520-016-3271-6
000128973 0247_ $$2pmid$$apmid:27189616
000128973 0247_ $$2ISSN$$a0941-4355
000128973 0247_ $$2ISSN$$a1433-7339
000128973 0247_ $$2altmetric$$aaltmetric:7597092
000128973 037__ $$aDKFZ-2017-04985
000128973 041__ $$aeng
000128973 082__ $$a610
000128973 1001_ $$0P:(DE-HGF)0$$aKuehl, Rea$$b0$$eFirst author
000128973 245__ $$aDeterminants of exercise adherence and contamination in a randomized controlled trial in cancer patients during and after allogeneic HCT.
000128973 260__ $$aBerlin$$bSpringer$$c2016
000128973 3367_ $$2DRIVER$$aarticle
000128973 3367_ $$2DataCite$$aOutput Types/Journal article
000128973 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524820213_12307
000128973 3367_ $$2BibTeX$$aARTICLE
000128973 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128973 3367_ $$00$$2EndNote$$aJournal Article
000128973 520__ $$aEvidence from randomized controlled trials is growing that exercise interventions are beneficial in cancer patients receiving allogeneic stem cell transplantation (allo-HCT). However, information about adherence to exercise interventions and exercise contamination in control groups is lacking. This information is crucial for the interpretation of study results. We therefore examined the determinants of exercise adherence and contamination in different treatment periods during (inpatient) and after (outpatient) allo-HCT.One hundred fifty-three patients scheduled for allo-HCT were randomized to a 1-year partly supervised exercise intervention (endurance and resistance exercise) or to a control group. Adherence was assessed via exercise logs and contamination via questionnaires.Adherence varied between 66 % (inpatient) and 78 % (outpatient) in different treatment periods. During (inpatient) transplantation period, higher adherence was significantly associated with lower fatigue (P = 0.004) and with having children at home (P = 0.049). Adherence after discharge was positively associated with endurance performance (P = 0.003); higher adherence after day 100 was associated with exercise activity prior allo-HCT (P = 0.010) and higher adherence after discharge (P = 0.001). Contamination among controls was high with 54 % and significantly associated with muscle strength (P = 0.025) and fatigue (P = 0.050).Exercise adherence in different treatment periods was determined by different variables, and contamination among controls was evident. These findings may have important implications for correct interpretation of randomized exercise intervention trials.
000128973 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000128973 588__ $$aDataset connected to CrossRef, PubMed,
000128973 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b1$$udkfz
000128973 7001_ $$aDreger, Peter$$b2
000128973 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b3$$udkfz
000128973 7001_ $$aBohus, Martin$$b4
000128973 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b5$$eLast author$$udkfz
000128973 773__ $$0PERI:(DE-600)1463166-0$$a10.1007/s00520-016-3271-6$$gVol. 24, no. 10, p. 4327 - 4337$$n10$$p4327 - 4337$$tSupportive care in cancer$$v24$$x1433-7339$$y2016
000128973 909CO $$ooai:inrepo02.dkfz.de:128973$$pVDB
000128973 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128973 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128973 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128973 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128973 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000128973 9141_ $$y2016
000128973 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128973 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128973 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128973 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128973 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSUPPORT CARE CANCER : 2015
000128973 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128973 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128973 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128973 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128973 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128973 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128973 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128973 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128973 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000128973 980__ $$ajournal
000128973 980__ $$aVDB
000128973 980__ $$aI:(DE-He78)G210-20160331
000128973 980__ $$aUNRESTRICTED